Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-06-30	PLN 18.70	-1.32%	9,643
26-06-29	PLN 18.95	-0.26%	1,537
26-06-26	PLN 19.00	+1.33%	9,352
26-06-25	PLN 18.75	0.00%	20,503
26-06-24	PLN 18.75	+2.74%	6,272

Delayed Quote Warsaw S.E.

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Warsaw S.E. Other stock markets 11:55:44 2026-06-30 EDT			5-day change	1st Jan Change
18.70 ^PLN	-1.32%		+3.89%	-23.67%

05-11	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	111M 29.4M 25.74M 23.76M 22.16M 41.76M 2.78B 42.5M 285M 1.37B 110M 108M 4.78B	P/E 2026 *	-3.56x	P/E 2027 *	4.88x
Enterprise Value	102M 27.09M 23.71M 21.89M 20.42M 38.47M 2.56B 39.16M 263M 1.26B 102M 99.51M 4.4B	EV / Sales 2026 *	84.9x	EV / Sales 2027 *	0.71x
Free-Float	72.15%	Yield 2026 *	-	Yield 2027 *	-

05-11	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-10	PolTREG SA Moves Forward With European Registration Process For TREG Therapy In Type 1 Diabetes	CI
11-19	Poltreg S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Immuthera and Its Wholly Owned Subsidiary of Poltreg S.A Appoints Adrian Bot to Its Board of Directors	CI
25-09-10	Poltreg S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-04	PolTREG S.A. Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	CI
25-07-31	Poltreg and Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	CI
25-06-13	Poltreg Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy	CI
25-06-13	Poltreg Establishes U.S. Subsidiary Immuthera To Advance International Development Strategy	RE
25-05-15	PolTREG S.A. Announces Positive Ema Opinion on Pediatric Investigation Plan for PolTREG's Treg Therapy in Type 1 Diabetes	CI
25-05-14	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-16	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

03-10	PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes	GL
11-07	Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies	GL
25-08-04	PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	GL
25-07-31	PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	GL
25-07-04	Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions	GL

Poltreg S.A. Stock

Stocks

PTG

PLPLTRG00038

Biotechnology & Medical Research

Valuation: Poltreg S.A.

Chart: Poltreg S.A.

Latest news : Poltreg S.A.

Press Releases: Poltreg S.A.

News in other languages: Poltreg S.A.

Quotes and Performance

Course Extremes

Managers and Directors: Poltreg S.A.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

03-11	PolTREG poursuit la procédure d’enregistrement au niveau européen de sa thérapie à base de TREG destinée au traitement du diabète de type 1
03-11	PolTREG treibt das europäische Zulassungsverfahren für die TREG-Therapie bei Typ-1-Diabetes voran

1 day	-1.32%
1 week	+3.89%
Current month	-1.06%
1 month	-1.06%
3 months	+13.33%
6 months	-23.67%
Current year	-23.67%

1 week	17.95	19.8
1 month	17.5	19.8
Current year	16	28.6
1 year	16	36
3 years	16	65
5 years	16	73.9
10 years	16	73.9

Manager	Title	Age	Since
Piotr Trzonkowski CEO	Chief Executive Officer	-	2019-04-30
Marta Druch CTO	Chief Tech/Sci/R&D Officer	-	2021-10-31
Daniel Shelly PRN	Corporate Officer/Principal	-	2024-02-20

Director	Title	Age	Since
Oktawian Zbigniew Jaworek BRD	Director/Board Member	50	2021-05-20
Michal Dariusz Wnorowski BRD	Director/Board Member	53	-
Marcin Jerzy Mierzwiñski CHM	Chairman	-	2021-05-23

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POLTREG S.A.	-1.32%	+3.89%	-39.29%	-65.62%	29.86M
LONZA GROUP AG	+1.15%	+9.07%	-3.67%	+4.36%	46.62B
REVOLUTION MEDICINES, INC.	-2.77%	+12.95%	+407.40%	+614.26%	40.95B
IQVIA HOLDINGS INC.	-0.03%	+15.14%	+22.70%	-12.74%	32.26B
BEONE MEDICINES AG	-1.73%	+4.85%	+18.15%	+59.57%	32.24B
CELLTRION, INC.	-3.29%	+2.85%	+13.80%	+30.30%	25.53B
ASCENDIS PHARMA A/S	+1.15%	+16.98%	-	-	16.38B
MEDPACE HOLDINGS, INC.	-0.96%	+16.22%	+70.46%	+125.41%	15.27B
EUROFINS SCIENTIFIC SE	+0.56%	+8.00%	+12.65%	+21.35%	13.61B
IONIS PHARMACEUTICALS, INC.	-1.74%	+4.48%	+99.22%	+92.87%	13.34B
Average	-0.91%	+9.82%	+66.82%	+96.64%	23.62B
Weighted average by Cap.	-0.91%	+10.36%	+94.39%	+141.39%

	2026 *	2027 *
Net sales	1.2M 319K 279K 258K 240K 453K 30.15M 461K 3.09M 14.88M 1.2M 1.17M 51.84M	116M 30.94M 27.08M 25M 23.32M 43.93M 2.92B 44.72M 300M 1.44B 116M 114M 5.03B
Net income	-29.4M -7.81M -6.84M -6.31M -5.89M -11.1M -739M -11.29M -75.73M -365M -29.36M -28.7M -1.27B	24.2M 6.43M 5.63M 5.2M 4.85M 9.13M 608M 9.3M 62.33M 300M 24.16M 23.62M 1.05B
Net Debt	-8.7M -2.31M -2.02M -1.87M -1.74M -3.28M -219M -3.34M -22.41M -108M -8.69M -8.49M -376M	-28.4M -7.55M -6.61M -6.1M -5.69M -10.72M -714M -10.91M -73.15M -352M -28.36M -27.72M -1.23B